Treatment on advanced NSCLC: Platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials

Medical Oncology

Volumn 32, Issue 2, 2015, Pages

  Zhou, Jian Guo ^a   Tian, Xu ^b,c   Wang, Xue ^a   Tian, Jin Hui ^d   Wang, Yi ^a   Wang, Fei ^a   Zhang, Yu ^a   Ma, Hu ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c WUHAN UNIVERSITY   (China)

^d LANZHOU UNIVERSITY   (China)

Author keywords

Chemotherapy; Erlotinib; Meta analysis; Non small cell lung cancer

Indexed keywords

ERLOTINIB; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CHINESE BIOMEDICAL DATABASE; CNKI DATABASE; COCHRANE LIBRARY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WANFANG DATABASE; WEB OF SCIENCE; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PLATINUM COMPOUNDS; QUINAZOLINES;

EID: 84920829990     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0471-0     Document Type: Article

References (31)

1. Chen WQ, Zheng RS, Zhang SW, Zeng HM, Zou XN. The incidences and mortalities of major cancers in China, 2010. Chin J Cancer. 2014;33(8):402–5. doi:10.5732/cjc.014.10084.
2. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2014. doi:10.1016/S0140-6736(14)62038-9.
3. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013. doi:10.1016/S1470-2045(13)70254-7.
4. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006;24(24):3831–7. doi:10.1200/jco.2006.05.8073.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32. doi:10.1056/NEJMoa050753.
6. http://www.cancer.gov/cancertopics/druginfo/fda-erlotinibhydrochloride. 19 Aug 2014.
7. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl,version.4,2014.55–56.
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535.
9. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787–92. doi:10.1128/AAC.48.8.2787-2792.2004.
10. Tarro G, Perna A, Esposito C. Early diagnosis of lung cancer by detection of tumor liberated protein. J Cell Physiol. 2005;203(1):1–5. doi:10.1002/jcp.20195.
11. Julian PT Higgins SG. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011] Chapter 8: Assessing risk of bias in included studies. 2011.
12. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928.
13. Schünemann HJ, Oxman A. GRADE handbook for grading the quality of evidence and the strength of recommendations Version 3.2 [updated March 2009]. 2009.
14. Deeks JJ, Altman DG. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011] Chapter 9: Analysing data and undertaking meta-analyses. 2011.
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. doi:10.1002/sim.1186.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi:10.1136/bmj.327.7414.557.
17. Egger M, Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.
19. Xu YH, Lu S. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur J Surg Oncol. 2014;40(3):311–7.
20. Lee DH, Lee JS, Kim SW, Rodrigues-Pereira J, Han B, Song XQ, et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer. 2013;49(15):3111–21.
21. Boutsikou E, Kontakiotis T, Zarogoulidis P, Darwiche K, Eleptheriadou E, Porpodis K, et al. Docetaxel–carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther. 2013;6:125–34.
22. Stinchcombe TE, Peterman AH, Lee CB, Moore DT, Beaumont JL, Bradford DS, et al. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age>/=70 years) with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2011;6(9):1569–77. doi:10.1097/JTO.0b013e3182210430.
23. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–9.
24. Mok TSK, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(30):5080–7.
25. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol. 2007;25(12):1545–52.
26. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892–9.
27. Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, et al. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. J Thorac Oncol. 2012;7(6):1041–8. doi:10.1097/JTO.0b013e31824cc66c.
28. Lee J-K, Hahn S, Kim D-W, Suh KJ, Keam B, Kim TM, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311(14):1430–7.
29. Haaland B, Tan PS, de Castro G, Lopes G. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol. 2014;9(6):805–11.
30. Zhang Y, Sun Y, Wang L, Ye T, Pan Y, Hu H, et al. Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of phase III trials. Chest. 2014;145(3 Suppl):348A.
31. Zhao N, Zhang X-C, Yan H-H, Yang J-J, Wu Y-L. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer (Amsterdam, Netherlands). 2014;85(1):66–73.